Filing Flows › Keros Therapeutics (KROS) › Q1 2026
Keros Therapeutics (KROS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Keros Therapeutics (KROS) reported revenue of $367K for the first quarter 2026 (Q1 2026), -100% from a year earlier and -3% from the quarter before.
Keros Therapeutics, Q1 2026: revenue $367K (-100% year over year), net loss $23.7M, operating cash flow −$3.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $367K | -3% | -100% |
| Operating profit | −$25.9M | — | -117% |
| Net earnings | −$23.7M | — | -116% |
| Operating cash flow | −$3.5M | — | -102% |
What changed
Revenue was $367K in Q1 2026, down 100% year over year and down 3% from the previous quarter.
Operating costs exceeded revenue by $25.9M, an operating margin of -7051.0%. Total costs fell 56% while revenue fell 100%. The quarter ended with a net loss of $23.7M, wider than the previous quarter's $23.5M loss.
Operating cash flow was −$3.5M. Non-cash charges added back $403K of depreciation and $6.2M of share-based compensation. Working capital and other items added $13.6M. Capital expenditures of $73K exceeded it, leaving free cash flow of −$3.6M.
Questions
What was Keros Therapeutics' revenue in the first quarter 2026?
Keros Therapeutics (KROS) reported revenue of $367K for the first quarter 2026 (Q1 2026), -100% from a year earlier and -3% from the quarter before.
Source: Keros Therapeutics 10-Q on SEC EDGAR.